JP6884701B2 - 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 - Google Patents

置換アミノプリン化合物、その組成物、及びそれによる治療の方法 Download PDF

Info

Publication number
JP6884701B2
JP6884701B2 JP2017538172A JP2017538172A JP6884701B2 JP 6884701 B2 JP6884701 B2 JP 6884701B2 JP 2017538172 A JP2017538172 A JP 2017538172A JP 2017538172 A JP2017538172 A JP 2017538172A JP 6884701 B2 JP6884701 B2 JP 6884701B2
Authority
JP
Japan
Prior art keywords
purine
cyclohexanecarboxamide
ylamino
chloro
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017538172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530199A (ja
JP2017530199A5 (enExample
Inventor
アレクサンダー マシュー
アレクサンダー マシュー
バフマンヤル ソゴレ
バフマンヤル ソゴレ
フレドレリク ボーイラン ジョン
フレドレリク ボーイラン ジョン
ハンセン ジョシュア
ハンセン ジョシュア
フアング デフア
フアング デフア
フバード ロバート
フバード ロバート
ジェフィ ブランドン
ジェフィ ブランドン
レイステン ジム
レイステン ジム
モグハダム メフラン
モグハダム メフラン
ケイ．ラヘジャ ラジェ
ケイ．ラヘジャ ラジェ
レイモン ヘザー
レイモン ヘザー
シュワルツ キンバリー
シュワルツ キンバリー
スロス マリアンヌ
スロス マリアンヌ
トレス エドウアルド
トレス エドウアルド
ミンフ トラン タム
ミンフ トラン タム
ク シュイチャン
ク シュイチャン
ズハオ ジングジング
ズハオ ジングジング
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2017530199A publication Critical patent/JP2017530199A/ja
Publication of JP2017530199A5 publication Critical patent/JP2017530199A5/ja
Priority to JP2019182133A priority Critical patent/JP6987823B2/ja
Application granted granted Critical
Publication of JP6884701B2 publication Critical patent/JP6884701B2/ja
Priority to JP2021195105A priority patent/JP7196270B2/ja
Priority to JP2022199122A priority patent/JP2023027269A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017538172A 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 Active JP6884701B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2019182133A JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2022199122A JP2023027269A (ja) 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019182133A Division JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Publications (3)

Publication Number Publication Date
JP2017530199A JP2017530199A (ja) 2017-10-12
JP2017530199A5 JP2017530199A5 (enExample) 2018-11-15
JP6884701B2 true JP6884701B2 (ja) 2021-06-09

Family

ID=55632334

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017538172A Active JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2022199122A Pending JP2023027269A (ja) 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2022199122A Pending JP2023027269A (ja) 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Country Status (28)

Country Link
US (8) US9512124B2 (enExample)
EP (2) EP3204386B1 (enExample)
JP (4) JP6884701B2 (enExample)
KR (2) KR102504849B1 (enExample)
CN (2) CN113248506A (enExample)
AR (2) AR102171A1 (enExample)
AU (2) AU2015328414B2 (enExample)
CA (1) CA2963639C (enExample)
CL (1) CL2017000820A1 (enExample)
CO (1) CO2017003838A2 (enExample)
CY (1) CY1124173T1 (enExample)
DK (1) DK3204386T3 (enExample)
EA (1) EA201790779A1 (enExample)
EC (1) ECSP17026210A (enExample)
ES (2) ES2871142T3 (enExample)
HR (1) HRP20210656T1 (enExample)
HU (1) HUE054694T2 (enExample)
IL (2) IL251566B (enExample)
LT (1) LT3204386T (enExample)
MX (2) MX388321B (enExample)
PL (1) PL3204386T3 (enExample)
PT (1) PT3204386T (enExample)
RS (1) RS61884B1 (enExample)
SG (2) SG10202009598VA (enExample)
SI (1) SI3204386T1 (enExample)
SM (1) SMT202100302T1 (enExample)
TW (1) TW201629063A (enExample)
WO (1) WO2016057370A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023027269A (ja) * 2014-10-06 2023-03-01 シグナル ファーマシューティカルズ，エルエルシー 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233808B1 (en) 2014-12-16 2021-07-14 Signal Pharmaceuticals, LLC Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107635992B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 用作tnf抑制剂的三环杂环化合物
EA201792054A1 (ru) 2015-03-18 2018-01-31 Бристол-Майерс Сквибб Компани Гетероциклические соединения, применимые в качестве ингибиторов tnf
CA2980159A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
MX385379B (es) 2015-07-24 2025-03-18 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilciclohexanol e intermedios utiles en este.
MX2018001173A (es) 2015-08-03 2018-04-24 Squibb Bristol Myers Co Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.
CN109069512B (zh) * 2016-04-01 2022-06-14 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物以及相关治疗方法
PT3436019T (pt) * 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
CN109476696B (zh) * 2016-06-02 2022-06-10 细胞基因公司 动物及人抗锥虫和抗利什曼原虫剂
ES2926149T3 (es) * 2016-06-02 2022-10-24 Celgene Corp Agentes antipalúdicos animales y humanos
BR112020006599B1 (pt) * 2017-10-04 2024-02-20 Celgene Corporation Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida
US10590136B2 (en) * 2017-10-04 2020-03-17 Celgene Corporation Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
WO2022002118A1 (zh) * 2020-07-01 2022-01-06 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
CN101360725B (zh) 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
KR20150028857A (ko) 2006-10-27 2015-03-16 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
US8491930B2 (en) 2008-04-23 2013-07-23 Farmasierra Manufacturing, S.L. Pharmaceutical formulation containing ibuprofen and codeine
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
LT3204386T (lt) 2014-10-06 2021-07-12 Signal Pharmaceuticals, Llc Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023027269A (ja) * 2014-10-06 2023-03-01 シグナル ファーマシューティカルズ，エルエルシー 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Also Published As

Publication number Publication date
EP3204386B1 (en) 2021-03-03
EP3822274A1 (en) 2021-05-19
CY1124173T1 (el) 2022-05-27
CA2963639A1 (en) 2016-04-14
AU2015328414A1 (en) 2017-04-27
US20190336507A1 (en) 2019-11-07
AU2020201486A1 (en) 2020-03-19
AU2020201486B2 (en) 2021-07-08
RS61884B1 (sr) 2021-06-30
JP7196270B2 (ja) 2022-12-26
PT3204386T (pt) 2021-05-31
IL251566B (en) 2020-09-30
US20200237768A1 (en) 2020-07-30
NZ730753A (en) 2024-02-23
IL277069B (en) 2022-05-01
ES2871142T3 (es) 2021-10-28
US20170042902A1 (en) 2017-02-16
JP2022033858A (ja) 2022-03-02
US10398700B2 (en) 2019-09-03
CL2017000820A1 (es) 2017-12-15
HUE054694T2 (hu) 2021-09-28
US20230158035A1 (en) 2023-05-25
WO2016057370A1 (en) 2016-04-14
JP2020033352A (ja) 2020-03-05
DK3204386T3 (da) 2021-05-25
CN113248506A (zh) 2021-08-13
ES2980464T3 (es) 2024-10-01
CN107001372B (zh) 2021-04-27
KR102504849B1 (ko) 2023-03-02
US10149849B2 (en) 2018-12-11
MX2017004600A (es) 2017-06-30
US9737541B2 (en) 2017-08-22
JP2017530199A (ja) 2017-10-12
KR20170063740A (ko) 2017-06-08
SG11201702759XA (en) 2017-05-30
NZ767954A (en) 2024-02-23
ECSP17026210A (es) 2017-05-31
SG10202009598VA (en) 2020-10-29
TW201629063A (zh) 2016-08-16
JP6987823B2 (ja) 2022-01-05
CN107001372A (zh) 2017-08-01
BR112017006998A2 (pt) 2018-01-16
HRP20210656T1 (hr) 2021-07-23
CO2017003838A2 (es) 2017-07-11
SMT202100302T1 (it) 2021-07-12
EA201790779A1 (ru) 2017-09-29
EP3204386A1 (en) 2017-08-16
AR102171A1 (es) 2017-02-08
US20170296546A1 (en) 2017-10-19
AU2015328414B2 (en) 2020-03-19
US20210128565A1 (en) 2021-05-06
US9512124B2 (en) 2016-12-06
JP2023027269A (ja) 2023-03-01
IL277069A (en) 2020-10-29
LT3204386T (lt) 2021-07-12
US11590139B2 (en) 2023-02-28
EP3822274B1 (en) 2024-03-06
AR128748A2 (es) 2024-06-12
MX2021014531A (es) 2022-01-06
PL3204386T3 (pl) 2021-09-20
EP3204386A4 (en) 2018-04-18
US20160096841A1 (en) 2016-04-07
US20190091230A1 (en) 2019-03-28
US10646493B2 (en) 2020-05-12
IL251566A0 (en) 2017-05-29
SI3204386T1 (sl) 2021-08-31
KR20230035424A (ko) 2023-03-13
MX388321B (es) 2025-03-19
CA2963639C (en) 2023-07-04
US10940152B2 (en) 2021-03-09

Similar Documents

Publication Publication Date Title
JP6884701B2 (ja) 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
US9783505B2 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
US10420772B2 (en) Animal and human anti-trypanosomonal and anti-leishmania agents
BR112017006998B1 (pt) Composto de aminopurina substituído, composição farmacêutica compreendendo o mesmo, uso e método para preparar o referido composto e métodos in vitro e ex vivo de inibição de quinase
HK1241852B (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180928

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180928

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190604

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191003

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200602

C27C Written answer of applicant after an oral proceeding

Free format text: JAPANESE INTERMEDIATE CODE: C2721

Effective date: 20200714

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201210

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210309

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210413

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210512

R150 Certificate of patent or registration of utility model

Ref document number: 6884701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250